Hexarelin: Dosing Protocols

Research Dosing Disclaimer#

The dosing information presented below is derived from published clinical trials, preclinical studies, and pharmacological research. Hexarelin is not approved for therapeutic use in any jurisdiction, and no official dosing guidelines exist. This information is provided for educational and research reference purposes only.

Clinical Trial Dosing Data#

Acute GH Stimulation Studies#

Phase 2 clinical trials evaluating hexarelin as a growth hormone secretagogue have employed intravenous bolus doses ranging from 0.5 to 2.0 micrograms per kilogram body weight. These doses were administered as single injections for the purpose of assessing acute GH-releasing capacity.

The dose-response relationship for GH release in these studies followed a clear pattern. At 0.5 mcg/kg IV, hexarelin produced measurable GH elevation above baseline in both healthy volunteers and GH-deficient patients. At 1.0 mcg/kg IV, a robust GH response was observed, with peak serum GH concentrations typically occurring 15 to 30 minutes after injection. At 2.0 mcg/kg IV, near-maximal GH responses were achieved, with diminishing incremental benefit above this dose level, suggesting receptor saturation.

In GH-deficient patients, the magnitude of GH response to hexarelin was attenuated compared to healthy controls, reflecting reduced somatotroph reserve. However, hexarelin was still effective in eliciting GH release in the majority of GH-deficient subjects, confirming residual pituitary responsiveness to GHS-R1a stimulation in this population.

Subcutaneous Administration#

Subcutaneous dosing has been studied as an alternative to intravenous administration. Doses of 100 to 200 micrograms administered subcutaneously produce GH responses that are generally comparable to intravenous dosing, though with a slightly delayed time to peak GH concentration (approximately 20 to 45 minutes versus 15 to 30 minutes for IV) and modestly lower peak GH levels, consistent with the absorption kinetics of subcutaneous injection.

Dose-Response Relationship for GH Release#

The dose-response curve for hexarelin-induced GH release shows several important characteristics.

• Threshold dose: GH release is detectable at doses as low as 0.5 mcg/kg IV in healthy subjects, indicating high receptor sensitivity.
• Linear range: Between approximately 0.5 and 2.0 mcg/kg IV, GH release increases approximately proportionally with dose.
• Ceiling effect: Above 2.0 mcg/kg IV, incremental GH release plateaus, suggesting near-complete occupancy of available GHS-R1a receptors on somatotroph cells.
• Inter-individual variability: Substantial variation in GH response magnitude exists between individuals, influenced by age, body composition, baseline GH status, and somatostatin tone.

Desensitization and Chronic Dosing#

GH Response Attenuation#

The most pharmacologically significant consideration for hexarelin dosing is the desensitization of the GH response during sustained administration. Clinical data consistently demonstrate that daily hexarelin use produces progressive attenuation of peak GH levels, with significant blunting observed within one to two weeks of continuous daily dosing.

The mechanism of desensitization involves multiple processes operating concurrently. GHS-R1a receptor downregulation occurs through ligand-induced receptor internalization and reduced receptor expression at the cell surface. Increased hypothalamic somatostatin tone develops as a compensatory response to sustained GH elevation. Negative feedback through elevated IGF-1 levels further suppresses somatotroph responsiveness.

Pulsatile and Intermittent Dosing Rationale#

The desensitization phenomenon has led researchers to investigate intermittent dosing strategies designed to preserve GH responsiveness over longer periods. The physiological rationale for pulsatile dosing is grounded in the observation that endogenous GH secretion occurs in discrete pulses, primarily during sleep and in response to exercise, fasting, and stress. The somatotroph cells of the anterior pituitary are adapted to respond to episodic stimulation rather than continuous activation.

Intermittent dosing protocols that incorporate treatment-free intervals -- such as 5 days on followed by 2 days off, or alternate-day dosing -- have been proposed to allow partial receptor recovery during the off period. Preclinical data suggest that GHS-R1a receptor expression recovers substantially within 24 to 48 hours after cessation of agonist exposure, supporting the biological plausibility of intermittent approaches.

However, no controlled clinical trials have systematically compared continuous versus intermittent hexarelin dosing with regard to long-term GH response preservation, IGF-1 levels, or clinical outcomes. The optimal balance between dosing frequency and treatment-free intervals remains an open research question.

Timing Considerations#

In research protocols employing multiple daily doses, the timing of hexarelin administration relative to meals, sleep, and exercise may influence the GH response.

• Fasting state: GH response to hexarelin is generally greater when administered in a fasted state, as postprandial insulin and free fatty acid elevations suppress GH secretion.
• Pre-sleep dosing: Administration approximately 30 to 60 minutes before sleep may complement the natural nocturnal GH pulse, though this has not been validated in controlled hexarelin studies.
• Post-exercise: GH response may be augmented after exercise due to reduced somatostatin tone, though timing interactions with hexarelin have not been systematically studied.

Synergistic Dosing with GHRH#

The co-administration of hexarelin with GHRH analogs produces a synergistic GH response that significantly exceeds the additive effects of either compound alone. In clinical studies, the combination of hexarelin (1 mcg/kg IV) with GHRH (1 mcg/kg IV) produced GH peaks approximately two to three times greater than either peptide administered individually.

This synergy is exploited diagnostically to assess maximal pituitary GH reserve. In research contexts, combined protocols must account for the amplified GH and secondary hormonal responses, including greater cortisol elevation compared to hexarelin alone.

Secondary Hormonal Dose-Response#

Hexarelin's effects on cortisol and prolactin are dose-dependent. In clinical studies, cortisol elevation was minimal at 0.5 mcg/kg IV but became more pronounced at 1.0 to 2.0 mcg/kg IV. Similarly, prolactin increases were largely observed at higher dose ranges. This dose-dependence of secondary hormonal effects suggests that lower hexarelin doses may provide a more favorable ratio of GH release to unwanted hormonal stimulation, though this has not been formally optimized.

Reconstitution and Preparation#

Hexarelin is supplied as a lyophilized powder that requires reconstitution prior to use. The standard reconstitution procedure involves adding bacteriostatic water for injection slowly to the vial, directing the stream along the inner wall of the vial to avoid disrupting the lyophilized cake. The solution should be gently swirled, not shaken, until the powder is fully dissolved. Vigorous agitation can denature the peptide through mechanical stress and foaming.

Typical reconstitution volumes are 1 to 2 mL of bacteriostatic water per vial, yielding concentrations suitable for accurate volumetric dosing with insulin syringes. The reconstituted solution should be clear and colorless; solutions that appear cloudy or contain particulates should not be used.

Storage and Stability#

• Lyophilized powder: Store at minus 20 degrees Celsius for long-term storage. The lyophilized form is stable for extended periods under these conditions when protected from moisture. Short-term storage at 2 to 8 degrees Celsius is acceptable.
• Reconstituted solution: Refrigerate at 2 to 8 degrees Celsius immediately after preparation. Protect from light. Use within 2 to 4 weeks of reconstitution. Do not freeze the reconstituted solution, as freeze-thaw cycles can promote peptide aggregation and degradation.
• Handling: Use sterile technique for all reconstitution and withdrawal procedures. Alcohol-swab vial stoppers before each needle insertion. Avoid contaminating the solution with non-sterile materials.

Evidence Gaps#

• No controlled dose-optimization studies have been published for chronic hexarelin use
• The optimal intermittent dosing protocol to balance GH stimulation and desensitization prevention has not been determined
• Human pharmacokinetic data correlating hexarelin plasma concentrations with GH response magnitude are limited
• Dose adjustments for specific populations (elderly, obese, renally impaired) have not been established
• The long-term effects of pulsatile versus continuous hexarelin exposure on IGF-1 levels and clinical outcomes are unknown

Related Reading#

• Hexarelin overview and research guide
• Hexarelin side effects profile
• Hexarelin research evidence